Orexigen Therapeutics Inc (OREXQ)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3344 N. TORREY PINES CT. LA JOLLA, CA 92037

Orexigen Therapeutics, Inc. operates as a biopharmaceutical company focusing on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. Its lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II development. These two product candidates are designed based on the company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.

View SEC Filings from OREXQ instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) 0 (0.0%)
13F shares: 1 1 0.0% 0
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls 0
Total Puts 0 2 Thousand -100.0%
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OREXQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OREXQ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • 10% Owner
0 2019-05-31 0

MOGLIA STEPHEN A. VP & CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-03-15 0

FORBES MONICA VP & ACTING CFO

  • Officer
0 2018-02-27 0

NARACHI MICHAEL CEO & PRESIDENT

  • Officer
  • Director
0 2017-10-13 0

CANNELL THOMAS R EVP, COO, PRES GLOBAL COM PROD

  • Officer
0 2017-10-13 0

LYNCH THOMAS P. EVP, CHIEF ADMIN OFF, GC & SEC

  • Officer
0 2017-10-13 0

KEYES JASON A EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2017-10-13 0

FLYNN PETER D EVP, HEAD OF GLOBAL DEV

  • Officer
0 2017-10-13 0

DOVEY BRIAN H

  • Director
0 2017-07-14 0

BOCK LOUIS C

  • Director
0 2017-07-14 0

MAHAFFY PATRICK J

  • Director
0 2017-07-14 0

HONIG PETER

  • Director
0 2017-07-14 0

ZOTH LOTA S.

  • Director
0 2017-07-14 0

ENDICOTT DAVID J.

  • Director
0 2017-07-14 0

JORN DEBORA

  • Director
0 2017-07-14 0

BAUPOST GROUP LLC/MA

SAK CORP

KLARMAN SETH A

  • 10% Owner
22,268,399 2016-03-15 0

KLASSEN PRESTON EVP, GLOBAL DEVELOPMENT

  • Officer
10,160 2016-02-02 0

ACE HEATHER S EVP, GLOBAL HUMAN RESOURCES

  • Officer
0 2016-02-02 0

WEBER ECKARD

  • Director
0 2015-06-09 0

DIXON WENDY L

  • Director
0 2015-06-09 0

BOOTH MARK D CHIEF COMMERCIAL OFFICER

  • Officer
3,810 2015-02-26 0

TURNER HEATHER D SVP, GEN. COUNSEL & SECRETARY

  • Officer
0 2015-02-03 0

HAGAN JOSEPH P CHIEF BUSINESS OFFICER

  • Officer
0 2015-02-03 0

TURNER DANIEL K III

  • Director
555,916 2011-12-22 0

HALAK BRIAN K

  • 10% Owner
3,018,058 2011-12-22 0

VITULLO NICOLE

  • 10% Owner
3,018,058 2011-12-22 0

BLAIR JAMES C

  • 10% Owner
3,018,058 2011-12-22 0

TREU JESSE I

  • 10% Owner
3,018,058 2011-12-22 0

SCHOEMAKER KATHLEEN K

  • 10% Owner
3,018,058 2011-12-22 0

DP VII ASSOCIATES LP

  • 10% Owner
50,643 2011-12-22 0

DOMAIN PARTERS VII L P

  • 10% Owner
2,967,415 2011-12-22 0

VIVEASH DAWN SVP/HEAD OF REGULATORY AFFAIRS

  • Officer
0 2011-07-22 0

POWELL MICHAEL

  • Director
0 2011-06-02 0

LACOB JOSEPH

  • Director
0 2011-05-27 0

COOPER GRAHAM K CFO AND TREASURER

  • Officer
0 2011-01-18 0

KAMDAR KIM P.

  • 10% Owner
1,963 2011-01-01 0

BREEN DORON

SPHERA FUNDS MANAGEMENT LTD.

MOR ISRAEL

SENATOR RON

  • MEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUP
591,877 2010-08-06 0

ARKIN MOSHE

M. ARKIN (1999) LTD.

  • MEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUP
No longer subject to file 2010-07-12 0

DUNAYEVICH EDUARDO CHIEF MEDICAL OFFICER

  • Officer
0 2010-01-22 0

PISKORSKI WALTER SVP, TECHNICAL OPERATIONS

  • Officer
0 2010-01-22 0

SCAIFE MICHAEL C SR. VP, REGULATORY AFFAIRS

  • Officer
0 2009-05-27 0

BAUM CAROL A VP, COMMERCIALIZATION

  • Officer
0 2009-04-23 0

KIM DENNIS D SR. VP, CORPORATE DEVELOPMENT

  • Officer
0 2009-04-23 0

LANDBLOOM RONALD P VP, MEDICAL AND REGULATORY

  • Officer
0 2009-01-26 0

COWLEY MICHAEL A CHIEF SCIENTIFIC OFFICER

  • Officer
141,344 2008-08-28 0

MCKINNEY ANTHONY A CHIEF BUSINESS OFFICER

  • Officer
0 2008-08-27 0

BYMASTER FRANKLIN P VP, NEUROSCIENCE

  • Officer
0 2008-08-27 0

TOLLEFSON GARY D PRESIDENT AND CEO

  • Officer
  • Director
0 2008-08-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments